Frontier Biotechnologies

688221

The current Frontier Biotechnologies (688221) market capitalization is approximately CN¥8.47B, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, Frontier Biotechnologies's market cap fluctuates with changes in its share price and share count. Last updated: February 15, 2026 at 5:45 PM Eastern Time

In the most recently reported quarter, Frontier Biotechnologies (688221) generated CN¥44.73M in revenue, representing a +10.22% year over year change. Quarterly revenue results and expectations reflect underlying demand trends, pricing dynamics, product or service mix, seasonality, and broader macroeconomic conditions. Actual results may differ from consensus estimates as new information becomes available. Last updated: February 15, 2026 at 5:33 AM Eastern Time

In the most recently reported fiscal year, Frontier Biotechnologies (688221) generated net income of CN¥-0.20B, compared with CN¥-0.33B in the prior fiscal year, representing a +38.78% year over year change. Net income may be positive or negative and can fluctuate materially from year to year due to changes in operating performance, non-recurring or one-time items, accounting treatments, capital structure, and broader macroeconomic conditions. Last updated: February 15, 2026 at 5:33 AM Eastern Time

According to its latest quarterly filing, Frontier Biotechnologies (688221) reported EBITDA of CN¥-45.10M, representing a -166.87% year over year change. EBITDA is a non-GAAP measure and does not account for depreciation, amortization, interest expense, taxes, or capital expenditures. As a result, it should be considered alongside other financial metrics when assessing operating performance. Actual results may differ from estimates as company-specific or macroeconomic conditions evolve. Last updated: February 15, 2026 at 5:33 AM Eastern Time

As of the most recent reporting period, the company's debt-to-equity ratio stands at 0.38x, calculated as total debt divided by total shareholders' equity. A lower debt-to-equity ratio generally indicates a more conservative capital structure with less reliance on external borrowing, while a higher ratio suggests greater financial leverage and potentially higher sensitivity to interest rates, refinancing conditions, and earnings volatility. The debt-to-equity ratio should be interpreted in the context of the company's industry, business model, cash flow stability, and balance sheet composition. Last updated: February 15, 2026 at 5:33 AM Eastern Time

Based on the latest available data, Frontier Biotechnologies (688221) is currently trading at a last twelve months (LTM) P/E ratio of -50.04x. The P/E ratio reflects how much investors are willing to pay today for a dollar of earnings and can vary meaningfully over time due to changes in profitability, growth expectations, margin outlook, and earnings volatility. Last updated: February 15, 2026 at 5:45 PM Eastern Time

In the most recently reported quarter, Frontier Biotechnologies (688221) revenue was CN¥44.73M. Earnings per share (EPS) for the quarter were CN¥-0.17. Revenue and EPS surprises may be positive or negative and can influence near-term stock performance depending on expectations, forward guidance, and broader market and sector conditions. For a detailed history of analyst expectations versus reported results, view the full estimates vs. actuals track record here: 👉 Estimates vs. Actuals Last updated: February 15, 2026 at 5:33 AM Eastern Time

Frontier Biotechnologies (688221) does not currently pay a dividend. Over the last twelve months (LTM), the company paid CN¥0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future. Last updated: February 15, 2026 at 5:33 AM Eastern Time

Based on the latest available analyst coverage, Frontier Biotechnologies (688221) currently carries a not available consensus rating. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated: February 15, 2026 at 5:45 PM Eastern Time

Like other publicly traded stocks, Frontier Biotechnologies (688221) shares are bought and sold on stock exchanges such as SHSE and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for Frontier Biotechnologies (688221) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.

At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add 688221 to your watchlist.

Frontier Biotechnologies trades under the ticker symbol 688221 on the SHSE stock exchange. The ticker 688221 is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.

As of the most recently reported period, Frontier Biotechnologies (688221) employs approximately 302 people worldwide. Reported employee figures may fluctuate over time due to hiring activity, restructuring, automation initiatives, or changes in business strategy. Headcount data is typically disclosed in company filings and reflects full-time employees unless otherwise stated. Last updated: February 15, 2026 at 5:45 PM Eastern Time

Frontier Biotechnologies (688221) operates in a highly competitive market with companies that often have different business models, geographic exposure, and end markets. While no two companies are identical, the following firms are generally considered the closest Frontier Biotechnologies (688221) stock peers based on overlapping products, services, and competitive dynamics:Shanghai MicuRx Pharmaceutical (688373)Novoprotein Scientific (688137)ImmuneOnco Biopharmaceuticals (Shanghai) (1541)Wuhan YZY Biopharma (2496)JW (Cayman) Therapeutics Co. (2126)InventisBio (688382)Inventiva (IVA)GenFleet Therapeutics (Shanghai) (2595)Suzhou Ribo Life Science (6938)Jacobio Pharmaceuticals Group (1167) These peers may differ in size, business mix, financial profile, and strategic focus, but they are commonly referenced due to overlapping markets, customer segments, or competitive positioning relative to Frontier Biotechnologies.